Several studies were performed to investigate the association between CDKN2A/B rs4977756 polymorphism and the risk of glioma. However, the results were inconsistent. Thus, we performed this meta-analysis. Methods: Eleven studies including 12814 glioma patients and 21140 controls were included in the meta-analysis. The pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) was assessed. Results: CDKN2A/B rs4977756 polymorphism was significantly associated with an increased

more »

... of glioma (OR=1.25; 95% CI, 1.21-1.30; P<0.00001). In the subgroup analysis by race, CDKN2A/B rs4977756 polymorphism was significantly associated with an increased risk of glioma in Caucasian (OR=1.27; 95% CI, 1.22-1.31; P<0.00001). However, no significant association between CDKN2A/B rs4977756 polymorphism and glioma risk was found in Asian (OR=1.05; 95% CI, 0.92-1.21; P=0.45). Conclusions: This meta-analysis suggested that DKN2A/B rs4977756 polymorphism may be a risk factor of glioma.